<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333524</url>
  </required_header>
  <id_info>
    <org_study_id>IELSG44</org_study_id>
    <nct_id>NCT04333524</nct_id>
  </id_info>
  <brief_title>FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role</brief_title>
  <acronym>PIMENTO</acronym>
  <official_title>FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role: an International Multicenter Retrospective Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Extranodal Lymphoma Study Group (IELSG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Extranodal Lymphoma Study Group (IELSG)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general aim of the present study is to assess the role of PET for the staging and for the&#xD;
      assessment of response and outcome prediction in Marginal Zone Lymphoma (MZL). This study&#xD;
      will be conducted as a multicenter retrospective analysis of MZL for whom PET scan are&#xD;
      available as DICOM file for central review.&#xD;
&#xD;
      The study is designed as a retrospective collection of patients with MZL enrolled in the&#xD;
      prospective IELSG36 and IELSG38 trials sponsored by IELSG and in the observational NF10 study&#xD;
      sponsored by Federazione Italiana Linfomi (FIL), with the possibility to add additional cases&#xD;
      from participating institutions.&#xD;
&#xD;
      The study will be conducted on performed scans. No additional scan or procedure will be&#xD;
      required for study purposes.&#xD;
&#xD;
      The study will be divided into two sections with different aims:&#xD;
&#xD;
      Part A will be conducted to understand the role of PET for the staging of MZL. PET scans will&#xD;
      be analyzed and compared with data retrieved from CT scan and from other staging procedures,&#xD;
      also including bone marrow biopsy, ultrasound, and laboratory exams. This part of the study&#xD;
      will describe ability of PET to identify pathologic lesions and to contribute to staging&#xD;
      definition or to stage migration.&#xD;
&#xD;
      Part B will be conducted to validate standardized criteria for response assessment in MZL&#xD;
      including FDG-PET among procedures and to define the prognostic role of metabolic response in&#xD;
      MZL. For this purpose the primary endpoint for this part of the study is defined as the&#xD;
      progression free survival. Secondary endpoint will be Overall survival, and response rate&#xD;
      defined with conventional procedures and rate of histological transformation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A significant proportion of patients considered for this study will be retrieved from&#xD;
      previous observational prospective clinical studies. Data on clinical presentation, treatment&#xD;
      and follow-up will be obtained from the existing dataset of the previous protocols. For the&#xD;
      additional cases identified from clinical practice data will be collected from patient chart.&#xD;
      A unique study CRF will be prepared to collect all the required details.&#xD;
&#xD;
      Patients with histologically confirmed marginal zone lymphomas according to the current WHO&#xD;
      classification are registered in the study. Moreover, patients characteristics (PS, systemic&#xD;
      symptoms), Ann Arbor stage, laboratory parameters, serology for hepatitis C, B and human&#xD;
      immunodeficiency virus, bone marrow aspirate and biopsy data, data on treatment start and&#xD;
      end, chemotherapy details, final response defined according to Cheson 2014 and Matutes&#xD;
      criteria, date of last follow-up ,occurrence of any event (relapse, progression, death) with&#xD;
      date will be collected.&#xD;
&#xD;
      PET response will be initially coded according to local interpretation of scan report. All&#xD;
      FDG-PET, will be then centralized to perform a blinded independent review of staging and&#xD;
      response. Images will be centralized and examined by a panel of 3 nuclear medicine physicians&#xD;
      that will independently review the scans. Each case will be evaluated by two reviewers. In&#xD;
      case of discordant results a third reviewer will adjudicate the case.&#xD;
&#xD;
      Each patient enrolled in the study will be anonymized by assigning a unique identification&#xD;
      numerical code upon registration in the study. The unique identification code will be used to&#xD;
      record health-related data.&#xD;
&#xD;
      Anonymized PET data will be uploaded into the DICOM system by the responsible person of the&#xD;
      site.&#xD;
&#xD;
      Anonymized health-related data will be collected in the e-CRF. At each site, the responsible&#xD;
      of the research or a delegated person will complete the e-CRF.&#xD;
&#xD;
      Only the Study Chair and the Sponsor will have access rights for the health-related data and&#xD;
      will be responsible for protection of the data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between CT and PET</measure>
    <time_frame>At baseline</time_frame>
    <description>To correlate CT and PET results for stage definition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of enrollment until the date of first documented progression, or last follow up, or date of death from any cause, whichever came first, assessed up to a maximum of 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>From date of first response to the date of relapse, or last follow up, or date of death from any cause, whichever came first, assessed up to a maximum of 10 years</time_frame>
    <description>DoR is evaluated only for responding patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Marginal Zone Lymphoma</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Staging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Criteria for response assessment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with MZL enrolled in the prospective IELSG36 and IELSG38 trials and on the&#xD;
        observational NF10, with the possibility to add additional cases from participating&#xD;
        institutions&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. One of the following subtypes of Histology confirmed Indolent non-follicular B-cell&#xD;
             lymphoma:&#xD;
&#xD;
               -  Splenic MZL (bone marrow histology and/or splenic tissue);&#xD;
&#xD;
               -  Extranodal MZL or MALT (tissue biopsy);&#xD;
&#xD;
               -  Nodal MZL (lymph node biopsy).&#xD;
&#xD;
          2. Age over 18.&#xD;
&#xD;
          3. Availability of details on clinical presentation, treatment details and results, and&#xD;
             on follow-up.&#xD;
&#xD;
          4. Execution of PET at diagnosis or/and at end of treatment or/and at relapse.&#xD;
&#xD;
          5. Execution of CT scan with iodine contrast medium at diagnosis and at assessment of&#xD;
             response.&#xD;
&#xD;
          6. Patients with histologically confirmed marginal zone lymphomas according to the&#xD;
             current WHO classification are registered in the study. Diagnosis based on tru-cut&#xD;
             core-needle biopsies are permitted in the study.&#xD;
&#xD;
          7. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a diagnosis of Non Hodgkin Lymphoma other than MZL.&#xD;
&#xD;
          2. Scans images not available for whatever reason.&#xD;
&#xD;
          3. Cases diagnosed on fine needle aspiration cytology only.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Luminari, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AUSL IRCCS - Reggio Emilia (Italy)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Thieblemont, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Saint-Louis Hospital, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emanuele Zucca, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Oncology Institute of Southern Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>IELSG - Study Coordination Office</last_name>
    <phone>+41 91 811</phone>
    <phone_ext>9040</phone_ext>
    <email>ielsg@eoc.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefano Luminari, MD</last_name>
    <email>stefano.luminari@ausl.re.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René-Olivier Casasnovas, MD</last_name>
      <email>olivier.casasnovas@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>René-Olivier Casasnovas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Thieblemont, MD</last_name>
      <email>Catherine.Thieblemont@athp.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine Thieblemont, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc Ysebaert, MD</last_name>
      <email>Ysebaert.Loic@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Loïc Ysebaert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASO SS. Antonio e Biagio e C. Arrigo</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Zanni, MD</last_name>
      <email>manuela.zanni@ospedale.al.it</email>
    </contact>
    <investigator>
      <last_name>Manuela Zanni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi</name>
      <address>
        <city>Ponderano</city>
        <state>BI</state>
        <zip>13875</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annarita Conconi, MD</last_name>
      <email>Annarita.Conconi@aslbi.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Annarita Conconi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Oncologico Businco</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Veronica Usai, MD</last_name>
      <email>sara.v.usai@aob.it</email>
    </contact>
    <investigator>
      <last_name>Sara Veronica Usai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;G. Rodolico&quot;, AOU Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annalisa Chiarenza, MD</last_name>
      <email>annalisa.chiarenza@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Annalisa Chiarenza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS - Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluigi Reda, DM</last_name>
      <email>gianluigi.reda@policlinico.mi.it</email>
    </contact>
    <investigator>
      <last_name>Gianluigi Reda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés JM Ferreri, MD</last_name>
      <email>ferreri.andres@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Andrés JM Ferreri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Farina, MD</last_name>
      <email>Lucia.Farina@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Lucia Farina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatrice Mancuso, MD</last_name>
      <email>salvatrice.mancuso@unipa.it</email>
    </contact>
    <investigator>
      <last_name>Salvatrice Mancuso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Finotto, MD</last_name>
      <email>silvia.finotto@iov.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Finotto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Spirito Santo Pescara</name>
      <address>
        <city>Pescara</city>
        <state>PE</state>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa Pennese, MD</last_name>
      <email>elsapennese@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elsa Pennese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro di Riferimento Oncologico di Aviano</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Spina, MD</last_name>
      <email>mspina@cro.it</email>
    </contact>
    <investigator>
      <last_name>Michele Spina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico S. Matteo di Pavia</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Arcaini, MD</last_name>
      <email>luca.arcaini@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Luca Arcaini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Cavallo, MD</last_name>
      <email>f.cavallo@unito.it</email>
    </contact>
    <investigator>
      <last_name>Federica Cavallo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria di Terni</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Marina Liberati, MD</last_name>
      <email>marinal@unipg.it</email>
    </contact>
    <investigator>
      <last_name>Anna Marina Liberati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Ospedale di Circolo e Fondazione Macchi di Varese</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Merli, MD</last_name>
      <email>Michele.Merli@asst-settelaghi.it</email>
    </contact>
    <investigator>
      <last_name>Michele Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico GB Rossi</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isacco Ferrarini, MD</last_name>
      <email>isacco.ferrarini@univr.it</email>
    </contact>
    <investigator>
      <last_name>Isacco Ferrarini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Picardi, MD</last_name>
      <email>marco.picardi@unina.it</email>
    </contact>
    <investigator>
      <last_name>Marco Picardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AUSL IRCCS Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Luminari, MD</last_name>
      <email>stefano.luminari@ausl.re.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Luminari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpiteux Universitaires de Genève (HUG)</name>
      <address>
        <city>Geneva</city>
        <state>GE</state>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noémie Lang, MD</last_name>
      <email>Noemie.Lang@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Noémie Lang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Bellinzona</city>
        <state>TI</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuele Zucca, MD</last_name>
      <email>ielsg@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Emanuele Zucca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

